Vaxart Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Vaxart de 22.6% y 45.2% respectivamente, mientras que el BPA crecerá en un 12.7% al año.

Información clave

22.6%

Tasa de crecimiento de los beneficios

12.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	45.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:VXRT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	38	-96	-66	-89	4
12/31/2025	30	-89	-58	-76	4
12/31/2024	34	-77	-63	-68	3
9/30/2024	17	-72	-51	-51	N/A
6/30/2024	14	-76	-62	-62	N/A
3/31/2024	9	-82	-68	-67	N/A
12/31/2023	7	-82	-72	-70	N/A
9/30/2023	4	-89	-92	-86	N/A
6/30/2023	2	-101	-93	-86	N/A
3/31/2023	1	-108	-104	-94	N/A
12/31/2022	0	-108	-104	-95	N/A
9/30/2022	0	-105	-88	-81	N/A
6/30/2022	0	-93	-87	-81	N/A
3/31/2022	0	-80	-74	-68	N/A
12/31/2021	1	-70	-65	-60	N/A
9/30/2021	1	-64	-60	-55	N/A
6/30/2021	1	-54	-54	-50	N/A
3/31/2021	2	-47	-39	-37	N/A
12/31/2020	4	-32	-25	-24	N/A
9/30/2020	8	-25	-17	-17	N/A
6/30/2020	8	-22	-12	-12	N/A
3/31/2020	7	-19	-12	-12	N/A
12/31/2019	10	-19	-14	-13	N/A
9/30/2019	8	-17	-16	-15	N/A
6/30/2019	8	-18	-17	-16	N/A
3/31/2019	8	-22	-10	-9	N/A
12/31/2018	4	-18	-15	-15	N/A
9/30/2018	3	-15	-12	-11	N/A
6/30/2018	4	-12	N/A	-8	N/A
3/31/2018	5	-7	N/A	-16	N/A
12/31/2017	6	-12	N/A	-10	N/A
9/30/2017	9	-16	N/A	-9	N/A
12/31/2016	8	-19	N/A	-12	N/A
12/31/2015	0	-22	N/A	-15	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VXRT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que VXRT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que VXRT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (45.2% al año) de VXRT crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (45.2% al año) de VXRT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VXRT se prevé que sea elevada dentro de 3 años.

Vaxart Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 113%, EPS downgraded

Consensus revenue estimates increase by 865%

Price target increased by 11% to US$5.25

Consensus revenue estimates increase by 57%

Consensus revenue estimates decrease by 60%, EPS upgraded

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Price target decreased to US$7.75

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Ray Stapleton joins Vaxart as CTO

Vaxart, Inc. Announces Board Changes

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Price target decreased to US$9.75

Vaxart shareholders approve proposal to increase number of shares

Vaxart continues to lobby shareholders to vote to increase number of shares

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Vaxart: A Unique Vaccine Concern

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission